ABVX Stock Overview
ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France.
ABIVAX Société Anonyme Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||€17.92|
|52 Week High||€36.70|
|52 Week Low||€15.58|
|1 Month Change||-7.34%|
|3 Month Change||-13.64%|
|1 Year Change||-36.00%|
|3 Year Change||98.23%|
|5 Year Change||31.77%|
|Change since IPO||-14.67%|
Recent News & Updates
|ABVX||FR Biotechs||FR Market|
Return vs Industry: ABVX exceeded the French Biotechs industry which returned -41.6% over the past year.
Return vs Market: ABVX underperformed the French Market which returned -5.9% over the past year.
|ABVX Average Weekly Movement||10.0%|
|Biotechs Industry Average Movement||8.8%|
|Market Average Movement||5.9%|
|10% most volatile stocks in FR Market||10.0%|
|10% least volatile stocks in FR Market||3.4%|
Stable Share Price: ABVX is more volatile than 75% of French stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: ABVX's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of French stocks.
About the Company
ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn’s Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer.
ABIVAX Société Anonyme Fundamentals Summary
|ABVX fundamental statistics|
Is ABVX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ABVX income statement (TTM)|
|Cost of Revenue||€45.52m|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
Sep 15, 2022
|Earnings per share (EPS)||-2.47|
|Net Profit Margin||0.00%|
How did ABVX perform over the long term?See historical performance and comparison
Is ABIVAX Société Anonyme undervalued compared to its fair value and its price relative to the market?
Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ABVX (€17.92) is trading below our estimate of fair value (€67.98)
Significantly Below Fair Value: ABVX is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: ABVX is unprofitable, so we can't compare its Price-To-Earnings Ratio to the European Biotechs industry average.
PE vs Market: ABVX is unprofitable, so we can't compare its Price-To-Earnings Ratio to the French market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ABVX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ABVX is overvalued based on its Price-To-Book Ratio (8.4x) compared to the FR Biotechs industry average (2.8x).
How is ABIVAX Société Anonyme forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Future Growth Score3/6
Future Growth Score 3/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ABVX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.3%).
Earnings vs Market: ABVX is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: ABVX's is expected to become profitable in the next 3 years.
Revenue vs Market: ABVX is forecast to have no revenue next year.
High Growth Revenue: ABVX is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ABVX's Return on Equity is forecast to be high in 3 years time
How has ABIVAX Société Anonyme performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ABVX is currently unprofitable.
Growing Profit Margin: ABVX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ABVX is unprofitable, and losses have increased over the past 5 years at a rate of 29% per year.
Accelerating Growth: Unable to compare ABVX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ABVX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-6.2%).
Return on Equity
High ROE: ABVX has a negative Return on Equity (-116.13%), as it is currently unprofitable.
How is ABIVAX Société Anonyme's financial position?
Financial Health Score4/6
Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: ABVX's short term assets (€75.2M) exceed its short term liabilities (€36.5M).
Long Term Liabilities: ABVX's short term assets (€75.2M) exceed its long term liabilities (€38.2M).
Debt to Equity History and Analysis
Debt Level: ABVX has more cash than its total debt.
Reducing Debt: ABVX's debt to equity ratio has increased from 0.6% to 150.1% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ABVX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if ABVX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is ABIVAX Société Anonyme current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ABVX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ABVX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ABVX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ABVX's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as ABVX has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Prof. Dr. Hartmut J. Ehrlich, M.D. has been the Chief Executive Officer of ABIVAX S.A. since December 04, 2013. Prof. Dr. Ehrlich is a physician and global leader with 30 years in academia and in the biop...
CEO Compensation Analysis
Compensation vs Market: Hartmut's total compensation ($USD497.54K) is about average for companies of similar size in the French market ($USD479.65K).
Compensation vs Earnings: Hartmut's compensation has increased whilst the company is unprofitable.
Experienced Management: ABVX's management team is seasoned and experienced (5.3 years average tenure).
Experienced Board: ABVX's board of directors are considered experienced (7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 16.9%.
ABIVAX Société Anonyme's employee growth, exchange listings and data sources
- Name: ABIVAX Société Anonyme
- Ticker: ABVX
- Exchange: ENXTPA
- Founded: 2013
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: €300.249m
- Shares outstanding: 16.75m
- Website: https://www.abivax.com
Number of Employees
- ABIVAX Société Anonyme
- 5, rue de la Baume
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/27 00:00|
|End of Day Share Price||2022/05/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.